Roche Investor Relations ASCO Planner 2016

Transcription

1 Roche Investor Relations ASCO Planner 2016 Friday, June 3 Session Title: Pediatric Oncology I Date: Fri, June 3 Location: S504 Time: 3:00 PM - 6:00 PM Speaker Name: Veronique Minard-Colin 5:12 PM - 5:24 PM Results of the randomized Intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): Evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen. (Abstract #10507) Saturday, June 4 Session Title: The View Beyond Single-Agent Checkpoint Blockade Session Type: Clinical Science Symposium Location: Hall D1 Time: 8:00 AM - 9:30 AM Speaker Name: Jeffrey R. Infante, MD 8:24 AM - 8:36 AM A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors. (Abstract #101) F. Hoffmann-La Roche Ltd 4070 Basel Switzerland Investor Relations investor.relations@roche.com Tel Fax

2 Session Title: Lung Cancer Non-Small Cell Metastatic Speaker Name: David A. Smith, MD Poster Board: #351 Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR). (Abstract #9028) Session Title: Genitourinary (Prostate) Cancer Time: 1:00 PM - 4:30 PM Speaker Name: Johann S. De Bono, MD, MSc, PhD, FRCP, FMedSci, MB ChB Poster Board: #274 Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. abi alone in patients with metastatic castration-resistant prostate cancer (mcrpc) after docetaxel chemotherapy (A. MARTIN Study). (Abstract #5017) Session Title: Melanoma/Skin Cancers Time: 1:00 PM - 4:30 PM Speaker Name: Grant A. McArthur, MD, PhD, FRACP, MBBS, MB, BS Poster Board: #135 Efficacy of cobimetinib (C) and vemurafenib (V) in advanced BRAF-mutated melanoma patients (pts) with poor and favorable prognosis in the cobrim phase III study. (Abstract #9530) Session Title: Developmental Therapeutics Immunotherapy Location: Hall B1 Time: 1:15 PM - 4:15 PM Speaker Name: Samuel Funt, MD 2/6

3 2:39 PM - 2:51 PM Correlation of peripheral and intratumoral T-cell receptor (TCR) clonality with clinical outcomes in patients with metastatic urothelial cancer (muc) treated with atezolizumab. (Abstract #3005) Session Title: Hematologic Malignancies Leukemia, Myelodysplastic Syndromes, and Allotransplant Location: Arie Crown Theater Time: 3:00 PM - 6:00 PM Speaker Name: Tara L. Lin, MD 5:12 PM - 5:24 PM Phase Ib/2 study of venetoclax with low-dose cytarabine in treatment-naive patients age 65 with acute myelogenous leukemia. (Abstract #7007) Sunday, June 5 Session Title: Gastrointestinal (Colorectal) Cancer Location: Hall B1 Time: 8:00 AM - 11:00 AM Speaker Name: Johanna C. Bendell, MD 8:24 AM - 8:36 AM Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). (Abstract #3502) Session Title: Genitourinary (Nonprostate) Cancer Location: Hall D2 Time: 8:00 AM - 11:00 AM Speaker Name: Arjun Vasant Balar, MD 8:00 AM - 8:12 AM Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (muc): Primary analysis of IMvigor210 cohort 1.). (Abstract #LBA4500) 3/6

4 Session Title: Genitourinary (Nonprostate) Cancer Location: Hall D2 Time: 8:00 AM - 11:00 AM Speaker Name: Robert Dreicer, MD, MS 8:36 AM - 8:48 AM Updated efficacy and > 1-y follow up from IMvigor210: Atezolizumab (atezo) in platinum (plat) treated locally advanced/metastatic urothelial carcinoma (muc). (Abstract #4515) Session Title: Breast Cancer HER2/ER Speaker Name: Maura N. Dickler, MD Poster Board: #8 A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (BC). (Abstract #520) Session Title: Breast Cancer Triple-Negative/Cytotoxics/Local Therapy Speaker Name: Sylvia Adams, MD; Suzette Delaloge, MD; Adam Brufsky, MD, PhD; David Miles, MD Poster Board: #114 Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mtnbc). (Abstract #1009) Poster Board: #118 Overall survival of patients with HER2-negative metastatic breast cancer treated with a firstline paclitaxel with or without bevacizumab in real-life setting: Results of a multicenter national observational study. (Abstract #1013) Poster Board: #179 Cobimetinib (C) + paclitaxel (P) as first-line treatment in patients (pts) with advanced triplenegative breast cancer (TNBC): Updated results and biomarker data from the phase 2 COLET study. (Abstract #1074) Poster Board: #203a COLET (NCT ): A multistage, phase 2 study evaluating the safety and efficacy of 4/6

5 cobimetinib (C) in combination with paclitaxel (P) as first-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC). (Abstract #TPS1100) Session Title: Plenary Session Including the Science of Oncology Award and Lecture Session Type: Plenary Session Location: Hall B1 Time: 1:00 PM - 4:00 PM Chair and/or Co-Chairs: Julie Vose, MD, MBA, FASCO, University of Nebraska Medical Center; Lynn Mara Schuchter, MD, University of Pennsylvania Monday, June 6 Session Title: Hematologic Malignancies Leukemia, Myelodysplastic Syndromes, and Allotransplant Speaker Name: Daniel Aaron Pollyea, MD, MS Poster Board: #1 Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients 65 years ineligible for standard induction therapy. (Abstract #7009) Session Title: Hematologic Malignancies Lymphoma and Chronic Lymphocytic Leukemia Speaker Name: Matthew Steven Davids, MD, MMSc; Andrew David Zelenetz, MD, PhD Poster Board: #83 Safety, efficacy and immune effects of venetoclax 400 mg daily in patients with relapsed chronic lymphocytic leukemia (CLL). (Abstract #7527) Poster Board: #84 Integrated safety analysis of venetoclax monotherapy in chronic lymphocytic leukemia (CLL). (Abstract #7528) Poster Board: #122 Phase 1b study of venetoclax plus R- or G-CHOP in patients with B-cell non-hodgkin lymphoma. (Abstract #7566) 5/6

6 Session Title: Hematologic Malignancies Plasma Cell Dyscrasia Speaker Name: Shaji Kumar, MD Poster Board: #297 Phase I venetoclax monotherapy for relapsed/refractory multiple myeloma. (Abstract #8032) Session Title: Lung Cancer Non-Small Cell Metastatic Location: Arie Crown Theater Time: 9:45 AM - 12:45 PM Speaker Name: Hiroshi Nokihara, MD, PhD 12:09 PM - 12:21 PM Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study. (Abstract #9008) Session Title: Breast Cancer HER2/ER Date: Mon, Jun 6 Location: Hall D1 Time: 1:15 PM - 4:15 PM Speaker Name: Sara A. Hurvitz, MD; Ander Urruticoechea, MD 1:15 PM - 1:27 PM Pathologic complete response (pcr) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE). (Abstract #500) 2:27 PM - 2:39 PM PHEREXA: A phase III study of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) for patients (pts) who progressed during/after one line of H-based therapy in the HER2-positive metastatic breast cancer (MBC) setting. (Abstract #504) 6/6